Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

7.9%

6 terminated/withdrawn out of 76 trials

Success Rate

83.8%

-2.8% vs industry average

Late-Stage Pipeline

12%

9 trials in Phase 3/4

Results Transparency

0 of 31 completed trials have results

Key Signals

10 recruiting6 terminated

Enrollment reporting

Analytics

N/A

24(43.6%)

Phase 2

9(16.4%)

Phase 3

9(16.4%)

Phase 1/2

6(10.9%)

Phase 2/3

4(7.3%)

Phase 1

3(5.5%)

55Total

N/A(24)

Phase 2(9)

Phase 3(9)

Phase 1/2(6)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (76)

Showing 20 of 76 trials

NCT06080191Phase 1Recruiting

Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL

Role: lead

NCT07297914Phase 2/3Recruiting

Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL

Role: lead

NCT07602751Phase 1/2Recruiting

FMT for Pediatric SR-aGVHD

Role: lead

NCT03373097Phase 1/2Active Not Recruiting

Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors

Role: lead

NCT05298995Phase 1Recruiting

GD2-CAR T Cells for Pediatric Brain Tumours

Role: lead

NCT07808047Active Not Recruiting

Dynamic Pupil Variations and the Efficacy of Peripheral Defocus Spectacle Lenses in Slowing Myopia Progression

Role: lead

NCT03017326Phase 3Active Not Recruiting

Paediatric Hepatic International Tumour Trial

Role: collaborator

NCT06921993Not ApplicableRecruiting

Lung Ultrasound for Guiding Antibiotic Use in Pediatric Pneumonia

Role: collaborator

NCT06844877Recruiting

Italian NCL Registry: a Registry for NCL as an Integration Tool for Future Therapeutic Strategies

Role: collaborator

NCT07464561Not ApplicableCompleted

RESCCUE4 - Group CBT for Social Anxiety in Adolescents

Role: lead

NCT04787263Phase 1/2Active Not Recruiting

CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML

Role: lead

NCT06064903Phase 1/2Recruiting

CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL

Role: lead

NCT04301154Phase 1Completed

Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth

Role: collaborator

NCT06931730Not ApplicableRecruiting

Reprogramming Energy Homeostasis in Overweight Individuals Via Exercise, Cognitive, and Social Training

Role: lead

NCT03373071Phase 1/2Completed

Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL

Role: lead

NCT05796258Completed

Three-pronged Centralized Molecular Analysis to Optimize Detection of NTRK1,2,3 Fusions in Thyroid Cancer

Role: collaborator

NCT06677866Not ApplicableRecruiting

Group CBT in Adolescents With Fragile X Syndrome and in Adolescents With Autism Spectrum Disorder

Role: lead

NCT06645587Not ApplicableUnknown

Targeting Repetitive Behaviors in Autism Spectrum Disorder Via Transcranial Direct Current Stimulation

Role: lead

NCT06276244Completed

Trial Readiness and Endpoint Assessment in Congenital and Childhood Myotonic Dystrophy

Role: collaborator

NCT06316414Completed

Omalizumab in Severe Asthmatics With Food Allergy

Role: lead